89Zr-DFO-CZP

**89Zr-DFO-CZP** is a radiopharmaceutical imaging agent composed of certolizumab pegol (CZP), a PEGylated humanized monoclonal antibody fragment targeting tumor necrosis factor alpha (TNFα), conjugated to the chelator deferoxamine (DFO) and radiolabeled with the positron-emitting isotope zirconium-89 (^89Zr). This compound is designed for immuno-PET imaging to visualize and quantify TNFα expression in vivo. The primary application under investigation is in patients with rheumatoid arthritis, aiming to assess disease activity and potentially guide anti-TNF therapy selection. The agent binds specifically to human TNFα, allowing non-invasive visualization of inflammatory processes associated with rheumatoid arthritis[1][6]. Development has focused on early-phase clinical trials for imaging applications.

Other names

zirconium-89 Deferoxamine B Certolizumab pegolzirconium89 Deferoxamine B Certolizumab pegolzirconium 89 Deferoxamine B Certolizumab pegol[89Zr]DFO-CZPZr-89 Cimzia PET Imaging AgentZr89 Cimzia PET Imaging AgentZr 89 Cimzia PET Imaging Agent